Cargando…
Towards a commercial process for the manufacture of genetically modified T cells for therapy
The recent successes of adoptive T-cell immunotherapy for the treatment of hematologic malignancies have highlighted the need for manufacturing processes that are robust and scalable for product commercialization. Here we review some of the more outstanding issues surrounding commercial scale manufa...
Autores principales: | Kaiser, A D, Assenmacher, M, Schröder, B, Meyer, M, Orentas, R, Bethke, U, Dropulic, B |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4356749/ https://www.ncbi.nlm.nih.gov/pubmed/25613483 http://dx.doi.org/10.1038/cgt.2014.78 |
Ejemplares similares
-
Towards automated manufacturing of clinical scale gene-modified T cells
por: Drechsel, Katharina, et al.
Publicado: (2014) -
Minimizing leukemia escape: implementing a dual anti-CD20- and CD19-scFv-based chimeric antigen receptor (CAR)
por: Schneider, Dina, et al.
Publicado: (2015) -
Commercial Scale Manufacturing of Allogeneic Cell Therapy
por: Pigeau, Gary M., et al.
Publicado: (2018) -
Development of
the Commercial Manufacturing Process
for Nirmatrelvir in 17 Months
por: Allais, Christophe, et al.
Publicado: (2023) -
P66. Generating and characterising WT1-specific T cells – research towards adoptive tumour therapy
por: Schmied, S, et al.
Publicado: (2014)